Humacyte, Inc. Appoints Diane Seimetz to its Board of Directors
June 27, 2022 at 08:30 pm IST
Share
Humacyte, Inc. announced the appointment of Diane Seimetz, Ph.D., to its board of directors. Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and the company
delighted to welcome her to the Humacyte board, said Kathleen Sebelius, Chair of Humacytes board of directors.
Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves
toward commercialization of the Human Acellular VesselTM (HAV).
Dr. Seimetz brings more than 22 years of international drug development, partnering and managerial experience
in the biopharmaceutical industry to the Humacyte board. In 2013, she co-founded Biopharma Excellence and
served as its Chief Executive Officer until June 2021. Biopharma Excellence was acquired by the PharmaLex Group
in September 2020 and since July 2021, Dr. Seimetz has served as Principal Consultant. Dr. Seimetz currently
serves on the board of directors of Cumulus Oncology, as a member of the decision board of the Helmholtz
Validation Fund, and as an advisory board member of Temedica and the Aglaia Oncology Fund. Dr. Seimetz began
her professional career in 1999 with the Fresenius Healthcare Group and served as Executive Vice President of
its biotech division and Chief Scientific Officer with responsibility for international drug development from
2008 to 2013.
Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Companyâs scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.
HUMACYTE, INC. 
